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Key points 
• Lack of yolk sac hematopoiesis in the Ldb1-/- mouse results from a decreased 
number of hemangioblasts and a differentiation block. 
• Identification of genes and pathways regulated by Ldb1 in the hemangioblast 
reveals potential targets for early developmental manipulation. 
 
Abstract  
The first site exhibiting hematopoietic activity in mammalian development is the yolk 
sac blood island, which originates from the hemangioblast. Here we performed 
differentiation assays, as well as genome-wide molecular and functional studies in 
BL-CFCs to gain insight into the function of the essential Ldb1 factor in early 
primitive hematopoietic development. We show that the previously reported lack of 
yolk sac hematopoiesis and vascular development in Ldb1-/- mouse result from a 
decreased number of hemangioblasts and a block in their ability to differentiate into 
erythroid and endothelial progenitor cells. Transcriptome analysis and correlation 
with the genome-wide binding pattern of Ldb1 in hemangioblasts revealed a number 
of direct target genes and pathways misregulated in the absence of Ldb1. The 
regulation of essential developmental factors by Ldb1 defines it as an upstream 
transcriptional regulator of hematopoietic/endothelial development. We show the 
complex interplay that exists between transcription factors and signalling pathways 
during the very early stages of hematopoietic/endothelial development and the 
specific signalling occurring in hemangioblasts in contrast to more advanced 
hematopoietic developmental stages. Finally, by revealing novel genes and pathways, 
not previously associated with early development, our study provides novel candidate 
targets to manipulate the differentiation of hematopoietic and/or endothelial cells.  
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Introduction 
Primitive erythroid and endothelial progenitors emerge almost simultaneously in 
mesodermal blood islands from a common hemangioblast progenitor1 that is 
characterized by the expression of Flk1; the receptor for VEGF (Vascular Endothelial 
Growth Factor) (Fig. S1). The other mesodermal-derived lineage expressing Flk1 is 
the cardiovascular progenitor cell, which is distinguishable from the hemangioblast by 
PDGF (platelet-derived growth factor) receptor expression. The hemangioblast has 
been studied in mouse, chick and zebrafish embryos2 and its existence is supported by 
the observation that hematopoietic and endothelial progenitors share the expression of 
common genes.3-7  
Deletion of Flk1 leads to embryonic lethality between 8.5 and 9.5 dpc possibly due to 
the absence of yolk sac blood islands.8, 9 The hemangioblast stage can be more 
specifically studied in vitro through the differentiation of ES cells into embryoid 
bodies (EBs), widely considered as a relevant model of embryonic development. 
Within EBs blast colony forming cells (BL-CFCs) can generate blast colonies, able to 
differentiate into hematopoietic and endothelial progenitors. They are therefore 
considered as the in vitro equivalent of the hemangioblast.10  
Recently Li et al. demonstrated that Ldb1 is also required during primitive 
hematopoiesis in the mouse, for the development of megakaryocytes and the 
maintenance of long-term hematopoietic stem cells.11, 12 Ldb1 deletion is embryonic 
lethal after 9.5 dpc, with severe developmental defects including small size, anterior 
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truncation, absence of heart/foregut structures, impairment of yolk sac hematopoiesis 
and vascular development.13 However, no functional studies or molecular 
mechanisms are known describing Ldb1 function in early hemangioblasts. Ldb1 
molecular function has been well-studied in definitive erythropoiesis, where it plays 
an essential role by forming large transcriptional complexes with Gata1, Lmo2, Scl, 
E12/E47, HEB, Lyl1, E2-2, Cbfa2t3 (Eto2), Mtgr1, Cdk9, Lmo4,14 binding E-
box/GATA motifs genome-wide.15 
In this study, we generated Ldb1-/- ES cells and performed differentiation assays and 
genome-wide molecular and functional studies in BL-CFCs to unravel the function of 
Ldb1 in early primitive hematopoietic development. We showed that Ldb1 deletion 
actually results in two separate defects; a decreased number of hemangioblasts and 
their inability to differentiate further down the hematopoietic and endothelial lineages. 
To gain insight into the mechanism underlying these defects, we determined the direct 
and indirect targets of Ldb1 in these progenitor cells (in contrast to more advanced 
hematopoietic developmental stages). The genome-wide binding pattern of Ldb1 
revealed that it is directly bound to a number of gene loci involved in mammalian 
hematopoietic development. Their expression is misregulated in the absence of Ldb1 
placing it as one of the most upstream factors controlling hematopoietic development. 
Furthermore our study reveals novel genes and pathways that are potentially 
important for early hematopoietic/endothelial development and shows the complex 
interplay between transcription factors and signalling pathways in very early primitive 
development stage, providing novel candidate targets that can be used to manipulate 
the differentiation of hematopoietic and/or endothelial cells.  
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Methods 
Ldb1-/- ES cell line generation/genotyping 
Both Ldb1 alleles were inactivated using the same construct (Suppl. Methods/Fig. 
S2A). After targeting the first allele a single ES cell clone was transiently transfected 
with a Cre recombinase expressing vector to delete exons 1/2 and the PMC-neo 
cassette, followed by targeting of the second allele. Southern blotting confirmed 
homologous recombination and deletion. Ldb1 protein levels were determined in 
nuclear extracts from Ldb1+/+ and Ldb1-/- ES cells with anti-Ldb1 N-18 (Santa Cruz®, 
Cat. SC-11198).  
ES cell differentiation  
Ldb1+/+ and Ldb1-/- ES cells were grown in suspension at 10.000 cells/ml on non-
adherent dishes in IMDM medium (without Leukemia Inhibitory Factor (LIF)) with 
15% FCS, 1% P/S, 1% L-glutamine (Gibco, Cat.25030-08), 0.05µg/ml transferin 
(Roche, Cat.652-202), 0.05µg/ml ascorbic acid (Sigma, Cat.A-4544), 3µl/ml 
monothioglycerol (Sigma, Cat.M-6145) for day 4 EBs and 1.8µl/ml for day 6/day 8 
EBs. 5% protein free hybridoma medium II (Gibco, Cat.12040-077) was added for 
day 6/day 8 EBs.  
Blast Colony Forming Cell (BL-CFC) assay 
Day 4 EBs were disrupted with trypsin-EDTA and cells were transferred in 
methycellulose-based media with 10% FCS, 1% P/S, 1% L-glutamine, 0.25µg/ml 
transferin, 0.25µg/ml ascorbic acid, 2µl/ml monothioglycerol, 0.01µg/ml mIL6 (R&D 
Systems, Cat.406-ML), 0.005µg/ml hVEGF (R&D Systems, Cat.293-VE) for 3 days. 
Colonies were scored according to morphology and number under an inverted 
microscope.  
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Colony Forming Cell (CFC) assay 
Ldb1+/+ and Ldb1-/- day 6 EBs were disrupted with 2.5% collagenase. Cells were 
transferred in methycellulose-based media with 10% FCS, 1% L-glutamine, 
0.25µg/ml transferin, 0.25µg/ml ascorbic acid, 2µl/ml monothioglycerol, 5% protein 
free hybridoma medium II, 0.01µg/ml mIL6, 0.001µg/ml IL3 (R&D Systems, 
Cat.403-ML), 0.005µg/ml hIL11 (R&D Systems, Cat.418-ML), 0.003µg/ml GM-CSF 
(R&D Systems, Cat.415-ML), 4U/ml EPO (R&D Systems, Cat.959-ME), 0.005µg/ml 
TPO (R&D Systems, Cat.488-TO), 0.1 µg/ml SCF (R&D Systems, Cat.455-MC). Red 
primitive erythroid colonies and white macrophage colonies (composed of round cells 
growing in clumps) were identified microscopically after 6 days according to 
morphology and colour. 
Flow Cytometry 
Day 4 EB single cell suspensions were labelled with Flk1-PE clone Avas 12α1 (BD 
PharmigenTM, Cat.555308) in 1% BSA/PBS. Dead cells were excluded by Hoechst 
33258 (Molecular Probes). Flk1+ cells were sorted from day 4 EBs on FACSAria 
using the Diva 5.1 software (BD). Day 6/8 EB single cell suspensions were labelled in 
1% BSA/PBS with CD41-PE clone MWReg30 (Santa Cruz®, Cat.sc-19963) or CD31-
FITC clone MEC 13.3 (BD PharmigenTM, Cat.553372). Dead cells were excluded 
with 7-AAD (InvitrogenTM). FACS was performed on FACScan (Becton Dickinson) 
and analysed with Cell Quest.  
Flk1+ Blast Colony Forming Cell (BL-CFC) isolation 
Day 4 EBs were disrupted with dissociation buffer (StemPro Accutase-InvitrogenTM). 
Dead cells were removed by Lymphoprep separation. Magnetic-assisted cell sorting 
(MACS) was carried out with autoMACS® Pro Separator (Miltenyi Biotec) using 
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Anti-PE MicroBeads (Miltenyi Biotec) and the Flk1-PE clone Avas 12α1 (BD 
PharmigenTM) antibody. Purity was assessed by flow cytometry.  
Chromatin Immunoprecipitation (ChIP) sequencing 
ChIP-sequencing of endogenous Ldb1 (using anti-Ldb1 antibody N-18, Santa Cruz®) 
on Flk1+ BL-CFCs isolated from day 4 EBs was performed as previously described.15, 
16
  
Gene expression profiling 
RNA was isolated from Ldb1+/+ and Ldb1-/- Flk1+ cells with the QIAGEN RNeasy 
Mini Kit and integrity was checked on the Agilent 2100 Bioanalyzer.  
Microarray  
RNA was converted to biotin-labelled cRNA, hybridised on the Mouse Genome 430 
2.0 Array and analysed with the Affymetrix GeneChip® Scanner 3000 according to 
the manufacturer protocol.  
RNA sequencing 
RNA sequencing was performed on Illumina HiSeq 2000 platform according to the 
manufacturer instructions.  
 
* For ChIP/RNA sequencing and microarray bioinformatic analysis see supplemental 
methods. 
ChIP/RNA sequencing and microarray data sets described in this study have been 
deposited in the NCBI Gene Expression Omnibus (Accession Number: GSE43044). 
 
 
 
 
 9 
Results  
No primitive erythropoiesis in the Ldb1-/- mouse  
Generation of the Ldb1-/- mouse is presented in Fig. S2A-D. The first striking 
observation in the embryos is the complete absence of any blood or vasculature from 
the extra-embryonic yolk sac, which also fails to completely surround the whole 
embryo, showing that erythropoiesis and vascular development are severely impaired 
in the absence of Ldb1 (Fig.1A, in agreement with Li et al. 2011).11 Ldb1+/- mice were 
viable, able to breed and did not exhibit any of the phenotypic characteristics of the 
Ldb1-/- mice (not shown, 11).  
Ldb1-/- EBs contain no erythroid and less endothelial progenitor cells  
We additionally generated an Ldb1-/- ES cell line to carry out differentiation, 
molecular and functional studies in hemangioblast-equivalent cells. The second Ldb1 
locus allele in Ldb1+/- ES cells was deleted (Fig. S2E) and the absence of Ldb1 
protein confirmed by western blotting and immunofluoresence (Fig. S2F-G). The 
morphology and growth of Ldb1-/- ES cells appeared similar to normal ES cells (not 
shown and Li et al., 2011).11, 17 We then tested their differentiation potential into EBs. 
Since Ldb1+/- mice did not exhibit any phenotypic differences as compared to Ldb1+/+ 
mice they were not used for further investigations. Ldb1+/+ and Ldb1-/- EBs did not 
show any phenotypic differences at days 3 and 4 appearing similar in size and 
structure (Fig. 1B). However after 8 days we observed a striking absence of erythroid 
clusters within the Ldb1-/- EBs (Fig. 1B), correlating with the hematopoietic defect 
observed in the knock-out mouse. Of note, Ldb1-/- EBs survived at least until day 10 
without apparent apoptosis, but were more adherent than the wild type ones. After 10 
days the majority was found attached to the bottom of the culture dish (not shown). 
Colony Forming Cell (CFC) assays were performed to test the potential of Ldb1-/- EBs 
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to give rise to primitive erythroid and macrophage colonies. Both bright red primitive 
erythroid colonies and white macrophage colonies, present in Ldb1+/+ day 6 EBs, were 
absent in the Ldb1-/- cultures. This defect was fully rescued by exogenous re-
expression of Ldb1 (Fig. 1C,D), indicating that those effects are specifically due to 
the Ldb1 absence. In addition, the presence of primitive erythroid progenitors was 
examined by flow cytometry using CD41 (integrin alpha-IIb) as marker.18 Ldb1+/+ 
EBs contained 2.6% and 12% of CD41+ cells at day 6 and day 8 respectively, while 
Ldb1-/- EBs did not contain any CD41+ erythroid progenitor cells in accordance with 
the absence of primitive erythroid colonies in Ldb1-/- CFC cultures (Fig.1E). The 
presence of endothelial progenitors in day 6 and day 8 EBs was also examined using 
CD31 (PECAM-1) as a marker, since Ldb1-/- embryos suffer from a severe defect in 
vascular development.19 Day 6 and 8 Ldb1+/+ EBs contained 21% and 16% CD31+ 
cells respectively. These cells were also found to be present in Ldb1-/- EBs at the same 
time points but reduced to less than half when compared to wild type (Fig. 1E). 
Ldb1-/- EBs do not give rise to blast colonies 
We then investigated whether BL-CFCs, the in vitro hemangioblast equivalent, were 
present in the Ldb1-/- EBs. Day 4 BL-CFCs were isolated using the VEGF receptor 
Flk1 as a marker (Fig. S1). Flk1+ BL-CFCs were present in both Ldb1+/+ and Ldb1-/- 
EBs, however a striking difference was observed as Ldb1-/- EBs repeatedly contained 
half the number of Flk1+ cells (Fig. 1F). In three independent experiments, blast 
colony forming assays also showed that blast colonies did form in the wild type but 
not in the knockout cultures (Fig. 1G). In conclusion, BL-CFCs are present in Ldb1-/- 
EBs but fail to generate fully grown blast colonies. Ldb1-/- Flk1+ cells eventually die 
in culture (not shown). 
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Transcriptome analysis identifies the genes and associated signalling pathways 
active in BL-CFCs 
To gain insight into the gene expression network and signalling pathways involved in 
the maintenance of the hemangioblast in vitro equivalent cells, transcriptome analysis 
of Flk1+ BL-CFCs by RNA-sequencing showed 12,468 expressed genes. Pathway 
enrichment analysis of the expressed genes revealed the signalling pathways 
potentially active in these progenitor cells (Table 1, Column A).  
Ldb1 plays a specific and major role in the BL-CFCs gene regulatory network 
To identify the direct genomic targets of Ldb1 in Flk1+ BL-CFCs, ChIP (chromatin 
immunoprecipitation)-sequencing in sorted Flk1+ cells showed 4,252 significant Ldb1 
binding peaks. Of all genes expressed in Flk1+ cells over 1/4 or 3,264 genes contain 
Ldb1 peak(s) in their vicinity. The group of Ldb1-bound genes were found to 
participate in approximately half of the signalling pathways active in BL-CFCs (Table 
1, Columns A versus B).  
We compared the Ldb1 ChIP-sequencing dataset of primitive Flk1+ BL-CFCs to the 
Li et al. dataset in more committed adult hematopoietic Lin- bone marrow 
progenitors.11 This revealed that the majority of the 4,252 Ldb1 binding events in 
Flk1+ cells is specific to these early progenitor cells (79.6% or 3,384 binding events) 
(Fig. 2A). Of note, among those specific binding events, a few (respectively 35 and 
168 events) have also been detected in previously published Ldb1 ChIP-sequencing 
datasets from fetal liver or definitive erythroleukemic cells.15 We therefore excluded 
those 203 binding events from the 3,384 Flk1+-specific events for further 
investigation. The resulting 3,181 Flk1+-specific binding events are referred to as 
“Set1” and will be compared with “Set2”, the common binding events between Flk1+ 
cells and Lin- bone marrow cells (20.4% or 868 Ldb1 binding events in Flk1+ cells).  
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We then performed a functional study to identify genes and associated signalling 
pathways regulated by Ldb1 in BL-CFCs. Day 4 Ldb1-/- Flk1+ cells were used for 
microarray and RNA-sequencing. The corresponding gene expression profiles were 
compared to the one of wild-type Flk1+ cells. Of the 12,468 genes found to be 
expressed in Flk1+ cells, 2,675 genes were identified as differentially expressed 
between the Ldb1+/+ and the Ldb1-/- Flk1+ cells (Table S1). Of those, 1,424 genes were 
down-regulated (53.23%) and 1,251 were up-regulated (46.77%). The differentially 
expressed genes were classified into three independent sets, Set1*, Set2* and Set3 
respectively depending on whether they were included in the Ldb1-bound genes of 
Set1, Ldb1-bound genes of Set2 or were unbound in Flk1+ cells (Fig. 2B). 
Interestingly, the majority of Ldb1 direct targets (Set1* and Set2*) were observed 
down-regulated genes; 65% (483 genes) were down-regulated while 35% (259 genes) 
were up-regulated in Set1* and 69.3% (149 genes) were down-regulated with 30.7% 
(66 genes) up-regulated in Set2*. This trend is absent in indirect target genes (Set3), 
which present 46.1% (792 genes) and 53.9% (926 genes) of down- and up-regulated 
genes respectively. The fact that the majority of direct target genes is down-regulated 
as a result of Ldb1 deletion shows that Ldb1 primarily acts as a positive 
transcriptional regulator in BL-CFCs. However the 1/3 of up-regulated genes in this 
group suggests an additional role for Ldb1 complexes as repressors of transcription. A 
search for enriched DNA binding motifs carried-out on sequences targeted by Ldb1 in 
Set1 revealed the known E-box(Tal1):Gata motif (motif 5) in only 3,6% of peaks (114 
out of 3,181) (Fig. 3A, C). The motifs found with the highest frequency were those 
associated with Klf transcription factors (motif 1: 513 peaks out of 3,181 or 16%), 
SP1 (motif 2: 569 peaks or 18%) and PU.1 (motif 3: 333 peaks or 10%). In addition, 
3% of Ldb1 peaks from Set1 are associated with a CTCF motif (motif 8: 98 out of 
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3,181 peaks) (Fig. 3A, C). Conversely, in Set2 peaks (common with adult bone 
marrow progenitor peaks), a prominent E-box:Gata motif was found (motif 1: 419 
peaks out of 868 or 48%) as described,11, 15 and no CTCF motif was detected (Fig. 3B, 
C). This suggests that Ldb1 forms different complexes in primitive Flk1+ cells 
targeting different regulatory sites. Alternatively, Ldb1 complex activity may be 
regulated by different co-factors in these cells as suggested by the differences in 
recognition motifs, potentially explaining the different repressing and activating 
transcriptional functions of Ldb1 in BL-CFCs. 
Ldb1 preferentially controls developmental genes in BL-CFCs and regulates a 
wide range of important signalling pathways 
Among the misregulated genes in Ldb1-/- Flk1+ BL-CFCs directly bound by Ldb1 
(Set1*), we found genes previously shown to participate in the regulation of mouse 
embryonic development and hematopoiesis such as Gata2,20, 21 Gata1,22 Runx1, 23 
Fli1,24 Lyl1,25 Id2, Id4,26 Klf4,27 Gfi1b,28 Cbfa2t3/Eto2,29 Myb,30 Dkk1, Sfrp1,31, 32 
Meis1,33 Raldh2,34 Fgfr2.35 The changes observed in some of those essential genes 
were confirmed by real-time PCR (Fig. S3). Of interest is the down-regulation of 
Stat5a and Sox7, Sox17 and Sox18 all having been reported as hematopoietic 
regulators. 36-38 Fig. 4 shows 4 examples of hematopoietic-essential Set1* genes. As 
BL-CFCs can differentiate into both the hematopoietic and endothelial lineages, we 
further analysed the hematopoietic and endothelial specific genes.39 Fig. 5 shows that 
the majority of these is down-regulated in the absence of Ldb1, illustrating the role of 
Ldb1 as an activator of transcription and to a lesser extent as a repressor in 
hematopoiesis and endothelial development (like the larger group of Set1* containing 
those genes, see Fig. 2B). 
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To decipher the essential functions of Ldb1 in the maintenance/differentiation of BL-
CFCs, we performed a pathway enrichment analysis on the total number of genes 
misregulated in Flk1+ cells in the absence of Ldb1 (Table 1, Column C). 
Approximately 1/3 (37 of 127) of the pathways enriched for genes expressed in Flk1+ 
cells are misregulated in the Ldb1-/- Flk1+ cells. To distinguish between direct and 
indirect functions of Ldb1, we carried out in parallel pathway enrichment analyses on 
the Ldb1 direct target genes (Set1* Table 1, Column D) and the indirect Ldb1-
regulated genes (Set3 Table 1, Column E). Approximately half of the misregulated 
pathways in the Ldb1-/- Flk1+ cells was directly targeted by Ldb1 (Table1 column C 
versus D). Among these, Acute Myeloid Leukemia, Basal cell carcinoma, Interleukin 
signalling pathway, Melanoma and T cell receptor signalling pathway were found. 
Four examples of perturbed signalling pathways are provided illustrating how the 
genes are affected by the absence of Ldb1 (Fig. S4-7). Signalling pathways such as 
WNT (Wingless), MAPK (Mitogen-Activated Protein Kinase), Hedgehog, ErbB, 
Focal adhesion, Integrin, Insulin, and Angiogenesis were commonly enriched for both 
direct and indirect genes of Set1* and Set3. Not unexpectedly we also found myeloid 
and lymphoid specific pathways in that context. In contrast, the VEGF-, EGF- 
(Epidermal Growth Factor), PDGF- (Platelet-Derived Growth Factor), and 
Endocytosis signalling pathways were enriched only in the indirect Set3 genes as 
compared to Set1*.  
In conclusion, the large number of pathways that are (potentially) affected in the 
Ldb1-/- Flk1+ BL-CFCs easily explains the severe phenotype of the Ldb1-/- embryos. 
Importantly, the fact that some Flk1+ cells still emerge during Ldb1-/- ES cell 
differentiation suggests that most of these pathways may play some role in 
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hemangioblast formation but become essential at subsequent developmental stages 
before the hematopoietic and endothelial lineages diverge. 
 
Discussion 
Primitive hematopoiesis begins in the yolk sac after the migration of brachyury 
expressing mesodermal cells through the primitive streak and their differentiation 
toward hematopoietic or endothelial precursors that collectively form blood islands. 
Hematopoietic precursors give rise to primitive erythroblasts and endothelial 
precursors to the vasculature. Both are absent in Ldb1-/- embryo yolk sacs, questioning 
the role of Ldb1 in this process. 
Many of the misregulated factors identified in the gene expression profiling of Flk1+ 
BL-CFCs from day 4 Ldb1+/+ and Ldb1-/- EBs act in the nuclear “response” of well 
known signalling pathways. WNT signalling has a positive role in regulating 
primitive hematopoiesis.32, 40 Addition of the inhibitor Dkk1 (down-regulated in the 
Ldb1-/- Flk1+ cells) blocks the pathway reducing the potential of BL-CFCs to generate 
colonies.31 Both WNT and Notch signalling pathways are involved in the 
differentiation of hemangioblast cells towards the primitive erythroid lineage. WNT 
signalling is active in Flk1+ BL-CFCs during the first hours of differentiation towards 
blast colonies, while Notch signalling remains inactive through Numb inhibition. 
Between 12 and 24 hours of differentiation the inhibitory effect exerted on Notch 
signalling is reduced and its activation leads to the expression of WNT inhibitors 
blocking the WNT pathway.31 Both pathways were found to be active in Flk1+ cells, 
however only WNT signalling was perturbed in Ldb1-/- Flk1+ cells. We propose that 
WNT misregulation can be attributed to changes in expression of genes bound by 
Ldb1. In Drosophila the importance of interplay between Notch, FGF (Fibroblast 
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Growth Factor), MAPK and EGFR signalling pathways has been documented as a 
requirement for blood specification, 41 with the last two pathways affected by the 
deletion of Ldb1 in Flk1+ cells.  
Changes in gene expression of the WNT signalling associated transcription factors 
Lef1, Tcf7 and Tcf7l1 in Ldb1-/- Flk1+ cells confirms the importance of this pathway in 
early hematopoiesis. The down-regulation of Etv2/Er71 in knockout cells leads to the 
same conclusion as it acts downstream of not only the WNT but also the BMP (Bone 
Morphogenic Protein) and Notch pathways.42, 43 Also expression of the TGF-β 
signalling receptors, endoglin and Alk-1 (Acvrlk1), was reduced in Ldb1-/- Flk1+ cells. 
ES cell knockout and rescue experiments showed that these receptors are important 
for hemangioblast development and primitive hematopoiesis.44 Recently Ldb1 has 
been implicated in cell migration and focal adhesion through an interaction with the 
Ste20-like kinase (SLK), a microtubule associated protein necessary for migration.45 
Our data show that expression of a number of focal adhesion proteins is affected, 
although SLK did not appear to change. Among the misregulated genes in Ldb1-/- 
Flk1+ BL-CFCs we found Stat5a, Sox7, Sox17 and Sox18. Interestingly, Stat5a over-
expression in differentiating ES cells leads to an increase in hematopoietic 
progenitors.36 Sox7, Sox18 and Sox17 participate in different stages of hematopoietic 
development in the mouse embryo with Sox7 and Sox18 being involved at the earliest 
stages of yolk sac hematopoiesis and Sox17 participating at later stages with the 
emergence of long-term repopulating hematopoietic stem cells.37, 38 
Ldb1 acts in a core complex with the essential hematopoietic regulators Scl, Lmo2, 
Gata1/Gata2, and associates with other essential factors such as Runx1.14, 15 When Scl 
is absent primitive hematopoiesis is impaired and hematopoietic colonies are absent in 
culture similar to Ldb1-/- embryo phenotype.20, 46, 47 In vitro generation of Scl-/- EBs 
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further showed that this factor is dispensable for hemangioblast generation, but 
essential for its commitment towards hematopoietic and endothelial lineages.48 Gata1 
deficient embryos fail to generate erythroid cells but Gata1 null ES cells can form 
other hematopoietic lineages.49, 50 Gata2 deficiency shows reduced yolk sac 
hematopoiesis and reduced number of ES cell derived colonies. Finally Lmo2 absence 
results in a phenotype similar to that of Scl and Gata2, although macrophage colonies 
were still present in colony assays.47 Our data show that all of these factors are 
regulated by Ldb1, placing it as a key regulator of the transcription factor network at 
the origin of the hematopoietic system. Accordingly, Ldb1 deletion in the mouse 
results in a more severe hematopoietic phenotype than observed with the factors 
mentioned above. The additional defect observed in endothelial development can also 
be explained by the EB results. There are still some CD31+ endothelial cells in the 
Ldb1-/- EBs, but their number is severely reduced. We conclude that the defect in 
primitive hematopoiesis in the absence of Ldb1 occurs at a stage in development 
before the hematopoietic and endothelial lineages diverge, i.e. Ldb1 is involved in the 
proliferation and differentiation of Flk1+ BL-CFCs resulting in half the number of 
BL-CFCs that do not develop into blast colonies when compared to normal.  
It is yet not clear how the hemangioblast develops from the embryonic mesoderm and 
how differentiation into hematopoietic and endothelial cells is regulated. Our data 
show that this must be a process that is orchestrated by a number of signal 
transduction pathways and transcription factors, many of which are directly or 
indirectly affected by the loss of Ldb1. One of the best studied transcription factors in 
hematopoietic development Runx1 is affected by the absence of Ldb1. It is expressed 
at low levels after the first 24 hours of blast colony formation and increases as the first 
hematopoietic progenitors of the erythroid and macrophage lineages emerge.31 
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Although Runx1-/- blast colonies and primitive hematopoietic colonies are still able to 
grow, 23 its absence results in the emergence of fewer colonies from EBs.31 Thus 
down-regulation of Runx1 in the Ldb1-/- EBs would be yet another cause of the 
decrease seen in the number of BL-CFCs. A large number of key hematopoietic 
transcription factors is misregulated in the absence of Ldb1, showing that this factor is 
critically required to properly orchestrate the gene expression network of 
hemangioblasts and their progeny (Fig. 6).   
A number of factors are also up-regulated and it is interesting to note that expression 
of the mesodermal marker brachyury in Ldb1-/- BL-CFCs and Ldb1-/- EBs is up-
regulated (data not shown). Brachyury expression is lost within the first 24 hours of 
blast colony formation 31 and our data show that it is suppressed by Ldb1. The 
brachyury up-regulation also suggests that Ldb1-/- BL-CFCs have not yet lost their 
mesodermal identity/properties and are therefore unable to differentiate into blast 
colonies.  
Finally our data also show that a number of genes involved in cardiovascular 
development are affected suggesting that Ldb1 is also important in cardiovascular 
development presumably in complex with the cardiac Gata factors. 
In summary Ldb1 was identified as an essential regulator of mouse hemangioblast 
proliferation and differentiation. The severity of the hematopoietic phenotype is the 
result of a decreased number of hemangioblast cells and their inability to differentiate 
further down the hematopoietic and endothelial lineages. The expression of essential 
transcription factors is directly affected by Ldb1, revealing its crucial role in the early 
hematopoietic/endothelial regulatory networks (Fig.6). In addition the identification 
of Ldb1 target genes in Flk1+ cells reveals a number of novel pathways contributing 
 19 
to hematopoietic/endothelial development and provides better understanding of the 
early developmental steps of these lineages. 
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Legends  
Table 1: Signalling pathways enriched in Ldb1+/+ and Ldb1-/- derived Flk1+ cells.  
Column A: Signalling pathways enriched for genes expressed in Flk1+ cells. Column 
B: Signalling pathways enriched for genes expressed in Flk1+ cells and bound by 
Ldb1. Column C: Signalling pathways perturbed in Ldb1-/- Flk1+ cells. Column D: 
Signalling pathways enriched with genes differentially expressed in Ldb1-/- Flk1+ cells 
and bound by Ldb1 (Set1*). Column E: Signalling pathways enriched with genes 
differentially expressed in Ldb1-/- Flk1+ cells and not bound by Ldb1 (Set3). The 
presented signalling pathways were selected based on significance (p-value ≤ 0.05) 
unless stated otherwise. Stars (*) indicate a p-value between 0.07-0.09. 
Figure 1: Ldb1 deletion leads to defects in primitive hematopoiesis and 
hemangioblast development.  
(A) At 9.5 dpc the blood and a vascular network in the Ldb1-/- embryo yolk sac is 
completely absent. (B) Ldb1+/+ and Ldb1-/- ES cells were differentiated into EBs. 
After 3 and 4 days Ldb1+/+ and Ldb1-/- EBs look similar. After 8 days Ldb1-/- EBs lack 
erythroid clusters (grey arrows). (C) CFC assay with cell suspensions from Ldb1+/+ 
and Ldb1-/- day 6 EBs. Primitive erythroid and macrophage colonies were able to 
grow from Ldb1+/+ but not Ldb1-/- cultures. (D) CFC assay with cell suspensions from 
Ldb1+/+ and Ldb1-/- day 6 EBs as well as Ldb1-/- EBs at day 6 expressing exogenous 
Ldb1. The colonies that formed were counted as primitive erythroid or macrophage 
colonies according to morphology and colour. The figure shows that while Ldb1 
absence impairs the formation of primitive erythroid and macrophage colonies, this 
phenotype can be rescued with Ldb1 expression. (E) FACS analysis of day 6 and day 
8 Ldb1+/+ and Ldb1-/- EBs. CD41+ primitive erythroid progenitors are not present in 
the Ldb1-/- EBs that contain less than half the number of CD31+ endothelial cells in 
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comparison with the Ldb1+/+ EBs. Cell suspensions were stained with either CD41-PE 
or CD31-FITC. CD41-PE+ cells are detected through the Fl2 channel and CD31-
FITC+ cells were detected through the Fl1 channel. (F) FACS analysis of day 4 EBs. 
Ldb1-/- EBs contain approximately 50% less Flk1+ BL-CFCs than Ldb1+/+ EBs. (G) 
Ldb1+/+ Flk1+ BL-CFCs give fully grown blast colonies but Ldb1-/- Flk1+ BL-CFCs do 
not.  
Figure 2: Genome-wide Ldb1 binding in BL-CFCs versus adult hematopoietic 
progenitor cells and transcriptional function of Ldb1 on BL-CFC gene 
expression. 
(A) Venn diagram comparing Ldb1 binding events in Flk1+ BL-CFCs versus Lin- 
bone marrow hematopoietic progenitor cells.11 (B) Correlative crossing between Ldb1 
ChIP-sequencing dataset in BL-CFCs and gene expression dataset of Ldb1-/- versus 
Ldb1+/+ BL-CFCs. 
Figure 3: Enrichment in DNA binding motifs within BL-CFC Ldb1 binding 
peaks. 
(A) Most prevalent motifs enriched within Ldb1 binding peaks of Set1. (B) Most 
prevalent motifs enriched within Ldb1 binding peaks of Set2. Frequency of each 
motif within the total number of studied binding peaks is given. (C) Each identified 
motif has been associated with one or more transcription factors found in the JASPAR 
database and the significance of this association is determined by the p-value. Please 
note that each factor represents a family of transcription factors binding the same 
motif.  
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Figure 4: Bubble plot representation of Ldb1 binding peaks around 4 selected 
hematopoiesis-specific genes down-regulated in the Ldb1-/- BL-CFCs. 
Each of the figures A-D are divided into three panels. The upper panel shows the 
studied gene and the neighbouring genomic genes. The middle panel shows the 
differential expression (presented as log2fold change on the y-axis) of the studied 
gene in Ldb1-/- Flk1+ cells in correlation with the Ldb1 binding peaks identified within 
or around the gene body. The light grey colour given to the circles (allocated to 
binding peaks) represents down-regulation of gene expression. On the bottom panel 
ChIP binding peak heights are represented on the y-axis and genome location on the 
x-axis. The dark grey colour represents Ldb1 ChIP peaks and the black colour 
represents IgG ChIP peaks (used as control).  
Figure 5: Bubble plot representation of Ldb1 binding peaks around 
differentially regulated developmental hematopoietic/endothelial genes in Ldb1-/- 
BL-CFCs. 
Each bubble in the plot represents one Ldb1 binding peak allocated to a hematopoietic 
specific gene (purple bubble), an endothelial specific gene (yellow bubble) or a gene 
involved both in hematopoietic/endothelial development (red bubble). The distance of 
each binding peak relative to a transcription start site (TSS) of each gene is 
represented on the x-axis, while changes in gene expression in the Ldb1-/- versus 
Ldb1+/+ Flk1+ cells are represented on the y-axis as the log2fold change. The height of 
the binding signal/peak is represented by the diameter of the bubble.  
Hematopoietic and endothelial specific genes were identified through the use of IPA 
(Ingenuity® Systems, www.ingenuity.com) and showed a 13.67% (29 out of 212 
genes) overlap with the subset of endothelial genes identified through the study of 
Takase et al. 2012.39 The lists of hematopoietic and endothelial specific genes as well 
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as the common hematopoietic/endothelial genes used to generate the plot are provided 
in Table S2.  
Figure 6: Speculative model of Ldb1 function in hemangioblast cells.  
Schematic representation of Ldb1 functions in the hemangioblast based on whole 
genome and transcriptome analyses, revealing Ldb1 involvement in the regulation of 
key hematopoietic gene expression and essential developmental signalling pathways.  
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Table 1 
 
 
 
Pathways 
Column A Column B Column C Column D Column E 
Signalling 
pathways 
enriched with 
genes  expressed 
in Flk1+ cells 
Signalling 
pathways 
enriched with 
genes  expressed 
in Flk1+ cells 
(and bound by 
Ldb1) 
Signalling 
pathways 
perturbed in 
Ldb1-/- Flk1+ 
cells 
Signalling 
pathways 
perturbed in 
Ldb1-/- Flk1+ cells 
(and bound by 
Ldb1) (Set1*) 
Signalling 
pathways 
perturbed in 
Ldb1-/- Flk1+ cells 
(and not bound 
by Ldb1) (Set3) 
Focal adhesion √ √ √ √ √ 
Adherens junction √ √ √ √ √ 
Angiogenesis √ √ √ √ √ 
Colorectal cancer √ √ √ √ √ 
Hedgehog signalling pathway √ √ √ √ √ 
ErbB signalling pathway √ √ √ √ √ 
Insulin signalling pathway √ √ √ √ √ 
Integrin Signalling Pathway √ √ √ √ √ 
Leukocyte transendothelial migration √ √ √ √ √ 
Pathways in cancer √ √ √ √ √ 
MAPK signalling pathway √ √ √ √ √ 
Regulation of actin cytoskeleton √ √ √ √ √ 
Wnt signalling pathway √ √ √ √ √ 
Acute myeloid leukemia √ √ √ √  
Basal cell carcinoma 
 √ √ √  
Interleukin signalling pathway √* √* √* √  
Melanoma √ √ √ √  
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T cell receptor signalling pathway √ √ √ √  
VEGF signalling pathway √ √ √  √ 
Apoptosis √ √ √  √ 
Axon guidance √ √ √  √ 
Chronic myeloid leukemia √ √ √  √ 
PDGF Signalling Pathway √ √ √  √ 
Small cell lung cancer √ √ √  √ 
EGF Signalling Pathway √* √ √  √ 
Endocytosis √ √ √  √ 
Glioma √ √ √  √ 
Neurotrophin signalling pathway √ √ √  √ 
TGF-beta signalling pathway √ √ √  √ 
Prostate cancer √ √ √   
Pancreatic cancer √ √ √   
uCalpain and friends in Cell spread 
 √ √   
Bladder cancer √  √  √ 
Dopamine receptor mediated  
signalling pathway √*  √  √ 
Tight junction √  √  √ 
Oxidative stress response √  √  √ 
Melanogenesis √  √   
B cell activation √  √   
Telomeres, Telomerase, Cellular Aging, 
and  Immortality √  √   
Cell cycle √ √  √  
mTOR signalling pathway √ √  √  
Ras Pathway √ √   √ 
Glutathione metabolism √    √ 
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Control of Gene Expression by  
Vitamin D Receptor √* √    
Aminoacyl-tRNA biosynthesis √ √    
Amyotrophic lateral sclerosis (ALS) √ √    
B cell receptor signalling pathway √ √    
Basal transcription factors √ √    
Endometrial cancer √ √    
Glyoxylate and dicarboxylate metabolism √ √    
Heme biosynthesis √ √    
Huntington disease √ √    
Interferon-gamma signalling pathway √ √    
JAK/STAT signalling pathway √ √    
Lysosome √ √    
Transcription regulation  
by bZIP transcription factor √ √    
Adipocytokine signalling pathway √ √    
Alzheimer's disease √ √    
Ubiquitin mediated proteolysis √ √    
Non-small cell lung cancer √ √    
Nucleotide excision repair √ √    
Oxidative phosphorylation √ √    
p38 MAPK Signalling Pathway √ √    
p53 signalling pathway √ √    
Parkinson's disease √ √    
Proteasome √ √    
Renal cell carcinoma √ √    
Ribosome √ √    
RNA degradation √ √    
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Spliceosome √ √    
Apoptotic Signalling in Response  
to DNA Damage √     
Arginine and proline metabolism √     
Base excision repair √     
Biosynthesis of unsaturated fatty acids √     
Chemokine signalling pathway √     
Chondroitin sulfate biosynthesis √     
Circadian clock system √     
Citrate cycle (TCA cycle) √     
CXCR4 Signalling Pathway √     
Cysteine and methionine metabolism √     
DNA replication √     
Dorso-ventral axis formation √     
Endothelin signalling pathway √     
Fatty acid metabolism √     
Fc gamma R-mediated phagocytosis √     
fMLP induced chemokine gene expression 
in HMC-1 cells √     
Fructose and mannose metabolism √     
Gap junction √     
General transcription regulation √     
Glycerophospholipid metabolism √     
Glycosylphosphatidylinositol 
(GPI)-anchor biosynthesis √     
GnRH signalling pathway √     
HIV-I Nef: negative effector of  
Fas and TNF √     
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Homologous recombination √     
Hypoxia response via HIF activation √     
Influence of Ras and Rho proteins on G1 
to S Transition √     
Inositol phosphate metabolism √     
Keratan sulfate biosynthesis √     
Limonene and pinene degradation √     
Links between Pyk2 and Map Kinases √     
Long-term depression √     
Long-term potentiation √     
Lysine degradation √     
Mismatch repair √     
N-Glycan biosynthesis √     
Notch signalling pathway √     
One carbon pool by folate √     
Oocyte meiosis √     
Other glycan degradation √     
Phosphatidylinositol signalling system √     
Phospholipids as signalling intermediaries √     
Progesterone-mediated oocyte maturation √     
Propanoate metabolism √     
Purine metabolism √     
Pyrimidine metabolism √     
Pyruvate metabolism √     
Ras Signalling Pathway √     
Regulation of eIF4e and p7 S6 Kinase √     
RNA polymerase √     
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Role of BRCA1,  BRCA2 and ATR in 
Cancer Susceptibility √     
Role of Mitochondria in  
Apoptotic Signalling √     
Selenoamino acid metabolism √     
Signalling of Hepatocyte Growth  
Factor Receptor √     
Skeletal muscle hypertrophy is regulated 
via AKT/mTOR pathway √     
SNARE interactions in vesicular transport √     
Steroid biosynthesis √     
Amino sugar and nucleotide  
sugar metabolism √     
Valine, leucine and isoleucine degradation √     
Thyroid cancer √     
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